Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 9/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 8/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 8/20 | 0.36 |
| ▸ | PDE4A | P27815 | 7/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2486210 | 0.76 | CREBBP (0.36) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9834972 | 0.76 | ATAD2 (0.50) | ATAD2PGRPDK2PDK4PDE3B | |
| SCHEMBL10667579 | 0.74 | ATAD2 (0.49) | ATAD2PGRPDK2PDK4PDE3B | |
| SCHEMBL9836092 | 0.74 | ATAD2 (0.49) | ATAD2PGRPDK2PDK4PDE3B | |
| SCHEMBL9835182 | 0.74 | ATAD2 (0.49) | ATAD2PGRPDK2PDK4PDE3B | |
| SCHEMBL9835339 | 0.73 | ATAD2 (0.42) | ATAD2PGRPDK2PDK4PDE3B | |
| Bromide SCHEMBL10555130 | 0.73 | ATAD2 (0.47) | ATAD2PGRPDK2PDK4PDE3B | |
| SCHEMBL9835030 | 0.72 | ATAD2 (0.46) | ATAD2PGRPDK2PDK4PDE3B | |
| SCHEMBL9834593 | 0.72 | ATAD2 (0.46) | ATAD2PGRPDK2PDK4PDE3B | |
| SCHEMBL9834224 | 0.72 | ATAD2 (0.46) | ATAD2PGRPDK2PDK4PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714010-B2 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | claimed |
| US-20050261350-A1 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | claimed |
| EP-1598353-A1 | Pyrrolobenzimidazolones and their use as antiproliferative agents | Boehringer Ingelheim International GmbH (DE) | 2005-11-23 | — | — | EP | claimed |
| EP-0473963-A1 | Pyrrolobenzimidazoles, imidazobenzoxazinones, and imidazoquinolones, processes for their preparation and their use as well as compositions containing these compounds | Beiersdorf-Lilly GmbH (DE) | 1992-03-11 | — | — | EP | claimed |
| EP-1756112-B1 | PYRROLOBENZIMIDAZOLONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-20050261350-A1 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| EP-0473963-A1 | Pyrrolobenzimidazoles, imidazobenzoxazinones, and imidazoquinolones, processes for their preparation and their use as well as compositions containing these compounds | Beiersdorf-Lilly GmbH (DE) | 1992-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261350-A1 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | MKI67, CCNI, CCNA1 | ATAD2 2801/4885PGR 355/4885PDK2 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.